Results 1 to 10 of about 9,753 (209)
Evaluating the association between migraine treatments and tinnitus: Insights from the US Food and Drug Administration adverse event reporting system. [PDF]
PLoS ONETinnitus, a distressing condition that can significantly impair quality of life, has been associated with several medications, including triptans. This study aimed to explore the relationship between tinnitus and specific migraine treatments, focusing on
Yun Kim, Yeabin Yook, Su-Jin Rhee
doaj +2 more sources
A Pharmacovigilance Study from 2004 to 2024 Utilizing the FDA Adverse Event Reporting System (FAERS) Examines Ischemic Adverse Events Linked to Triptan Use in Migraine Therapy [PDF]
Journal of Pain ResearchNuo Xu,1 Xiaowen Lu2 1Department of Clinical Nutrition, The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, People’s Republic of China; 2Department of Neurosurgery, The First Affiliated Hospital of Shantou University ...
Xu N, Lu X
doaj +2 more sources
Acute headache treatment in idiopathic intracranial hypertension: treating to the phenotype? [PDF]
The Journal of Headache and PainBackground Effective acute headache treatment is essential for improving the quality of life in people with idiopathic intracranial hypertension (pwIIH).
Gabriel Bsteh +10 more
doaj +2 more sources
Pain Research and Management, 2000 In the past 10 years, there have been great advances in the understanding of the pathophysiology of the migraine. This has been due in part to the realization that the migraine attack can be blocked by activating the serotonin receptor, namely the 5 ...
Marek J Gawel
doaj +3 more sources
Managing migraine with over-the-counter provision of triptans: the perspectives and readiness of Western Australian community pharmacists [PDF]
PeerJ, 2019 Background Down-scheduling one or more triptans to Schedule 3 (Pharmacist Only Medicine) from Schedule 4 (Prescription Only Medicine) has been debated in Australia for a decade.
Shaid Booth +3 more
doaj +2 more sources
Scientific Reports, 2021 Migraine is prevalent during pregnancy. Antimigraine medications such as dihydroergotamine (DHE) and triptans have been associated with adverse pregnancy outcomes in individual studies but lack of consensus remains.
Anick Bérard +4 more
doaj +1 more source
Therapeutic Drug Monitoring, 2008 The triptans are a class of tryptamine-based drugs indicated for in the treatment of migraine headaches. The triptans act as serotonin (5-hydroxytriptamine) (5-HT) agonists by binding to various serotonin receptors, causing vasoconstriction and neuronal inhibition to alleviate migraines.
Offie P, Soldin +2 more
openaire +2 more sources
Multi-omic analyses of triptan-treated migraine attacks gives insight into molecular mechanisms
Scientific Reports, 2023 Migraine is a common, polygenic disorder that is characterized by moderate to severe headache attacks. Migraine attacks are commonly treated with triptans, i.e. serotonin receptor agonists.
Lisette J. A. Kogelman +10 more
doaj +1 more source
The Journal of Headache and Pain, 2023 Background Triptans are effective for many migraine patients, but some do not experience adequate efficacy and tolerability. The European Headache Federation (EHF) has proposed that patients with lack of efficacy and/or tolerability of ≥ 2 triptans ...
Ruth Ruscheweyh +11 more
doaj +1 more source
Headache in daily practice: What a physician needs to know
APIK Journal of Internal Medicine, 2021 Headache is a common presenting complaint encountered in the outpatient as well as inpatient settings. Appropriate diagnosis and treatment of the commonly encountered primary headaches, timely evaluation for secondary causes, and patient education are ...
Pooja Mailankody +2 more
doaj +1 more source